These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11249656

  • 1. Recent developments in mucosal delivery of pDNA vaccines.
    Barnes AG, Barnfield C, Brew R, Klavinskis LS.
    Curr Opin Mol Ther; 2000 Feb; 2(1):87-93. PubMed ID: 11249656
    [Abstract] [Full Text] [Related]

  • 2. DNA vaccines--challenges in delivery.
    Pachuk CJ, McCallus DE, Weiner DB, Satishchandran C.
    Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
    [Abstract] [Full Text] [Related]

  • 3. Novel strategies using DNA for the induction of mucosal immunity.
    McCluskie MJ, Davis HL.
    Crit Rev Immunol; 1999 Apr; 19(4):303-29. PubMed ID: 10530431
    [Abstract] [Full Text] [Related]

  • 4. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.
    Dietrich G, Spreng S, Favre D, Viret JF, Guzman CA.
    Curr Opin Mol Ther; 2003 Feb; 5(1):10-9. PubMed ID: 12669465
    [Abstract] [Full Text] [Related]

  • 5. Oral delivery of micro-encapsulated DNA vaccines.
    Jones DH, Clegg JC, Farrar GH.
    Dev Biol Stand; 1998 Feb; 92():149-55. PubMed ID: 9554269
    [Abstract] [Full Text] [Related]

  • 6. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses.
    Stevceva L, Abimiku AG, Franchini G.
    Genes Immun; 2000 Jun; 1(5):308-15. PubMed ID: 11196691
    [Abstract] [Full Text] [Related]

  • 7. The mechanism of naked DNA uptake and expression.
    Wolff JA, Budker V.
    Adv Genet; 2005 Jun; 54():3-20. PubMed ID: 16096005
    [Abstract] [Full Text] [Related]

  • 8. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Wilson KM, Ramsay AJ.
    Vaccine; 2005 Oct 10; 23(42):5009-21. PubMed ID: 15985317
    [Abstract] [Full Text] [Related]

  • 9. Jump-starting the immune system: prime-boosting comes of age.
    Woodland DL.
    Trends Immunol; 2004 Feb 10; 25(2):98-104. PubMed ID: 15102369
    [Abstract] [Full Text] [Related]

  • 10. Use of attenuated bacteria as delivery vectors for DNA vaccines.
    Daudel D, Weidinger G, Spreng S.
    Expert Rev Vaccines; 2007 Feb 10; 6(1):97-110. PubMed ID: 17280482
    [Abstract] [Full Text] [Related]

  • 11. Optimization and delivery of plasmid DNA for vaccination.
    Jechlinger W.
    Expert Rev Vaccines; 2006 Dec 10; 5(6):803-25. PubMed ID: 17184219
    [Abstract] [Full Text] [Related]

  • 12. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
    Xu G, Wang S, Zhuang L, Hackett A, Gu L, Zhang L, Zhang C, Wang H, Huang Z, Lu S.
    Vaccine; 2009 Jun 12; 27(29):3821-30. PubMed ID: 19443090
    [Abstract] [Full Text] [Related]

  • 13. Current status and future perspectives of DNA vaccine delivery by attenuated intracellular bacteria.
    Dietrich G.
    Arch Immunol Ther Exp (Warsz); 2000 Jun 12; 48(3):177-82. PubMed ID: 10912622
    [Abstract] [Full Text] [Related]

  • 14. DNA vaccines: vector design, delivery, and antigen presentation.
    Feltquate DM.
    J Cell Biochem Suppl; 1998 Jun 12; 30-31():304-11. PubMed ID: 9893284
    [Abstract] [Full Text] [Related]

  • 15. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells.
    Jilek S, Merkle HP, Walter E.
    Adv Drug Deliv Rev; 2005 Jan 10; 57(3):377-90. PubMed ID: 15560947
    [Abstract] [Full Text] [Related]

  • 16. The cellular basis of immune induction at mucosal surfaces by DNA vaccination.
    Barnfield C, Brew R, Tilling R, Rae A, Wheeler C, Klavinskis LS.
    Dev Biol (Basel); 2000 Jan 10; 104():159-64. PubMed ID: 11713815
    [Abstract] [Full Text] [Related]

  • 17. Bacterial ghosts as adjuvant particles.
    Riedmann EM, Kyd JM, Cripps AW, Lubitz W.
    Expert Rev Vaccines; 2007 Apr 10; 6(2):241-53. PubMed ID: 17408373
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen.
    Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S.
    Drug Deliv; 2009 May 10; 16(4):196-204. PubMed ID: 19514980
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.